Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04020211 · ClinicalTrials.gov registry record

HF10 Treatment of Chronic Knee Pain

A clinical trial, sponsored by Nevro.

Terminated
Registry status
3
Enrollment target

NCT04020211: Clinical Trial study, sponsored by Nevro.

NCT04020211 is a clinical trial that was terminated before completion, run by Nevro. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04020211 was terminated before completion, sponsored by Nevro.

TERMINATED
Registry status
3 participants
Enrollment target

Study Summary

This is a multi-center study where patients who meet the eligibility criteria will be treated with HF10 therapy for their chronic knee pain post-orthopedic surgery. The primary endpoint will be assessed at 3 months, but observational assessments will continue until study completion at 12 months following implant.

Primary Outcome

The OKS is a patient self-completion patient reported outcome containing 12 questions on activities of daily living with a recall period of 4 weeks. The OKS has been developed and validated specifically to assess function and pain after total knee replacement. The higher the score indicates improvement. The proportion of implanted subjects who are responders (achieved ≥ 50% pain relief) to HF10 therapy for treatment of their chronic, post-surgical knee pain or reporting at least a 4-point improv

Interventions

  • DEVICE Senza HF10 Therapy

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2019-03-14
Est. Completion 2019-12-12
Nevro

8 total trials

Why NCT04020211 stopped before completion

NCT04020211 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Senza HF10 Therapy is the first listed.

NCT04020211 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04020211 about?

NCT04020211 is a clinical study titled "HF10 Treatment of Chronic Knee Pain". This is a multi-center study where patients who meet the eligibility criteria will be treated with HF10 therapy for their chronic knee pain post-orthopedic surgery. The primary endpoint will be assessed at 3 months, but observational assessments will continue until study completion at 12 months foll...

What is the current status of trial NCT04020211?

This trial is currently terminated. The enrollment target is 3 participants. The study started on 2019-03-14. Estimated completion is 2019-12-12.

What interventions are being tested in trial NCT04020211?

The interventions under investigation include: Senza HF10 Therapy (DEVICE).

Who is sponsoring clinical trial NCT04020211?

This trial is sponsored by Nevro, which has 8 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04020211, the US trial registry maintained by the National Library of Medicine. NCT04020211 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.